US equities
|
SPCX
$167.08
▲+5.11%
NVDA
$236.38
▲+1.04%
MU
$1,064.50
▼-0.97%
TSLA
$378.71
▲+2.19%
MSFT
$525.15
▲+1.47%
SNDK
$1,709.06
▼-0.64%
INTC
$117.38
▼-1.64%
META
$744.85
▲+2.30%
SPCX
$167.08
▲+5.11%
NVDA
$236.38
▲+1.04%
MU
$1,064.50
▼-0.97%
TSLA
$378.71
▲+2.19%
MSFT
$525.15
▲+1.47%
SNDK
$1,709.06
▼-0.64%
INTC
$117.38
▼-1.64%
META
$744.85
▲+2.30%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Appili Therapeutics Inc
(OP:
APLIF
)
0.0066
UNCHANGED
Last Price
Updated: 3:06 PM EDT, Sep 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Appili Therapeutics Inc
< Previous
1
2
3
Next >
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Engages Spartan Capital as Lead Underwriter for Planned IPO
July 29, 2025
Via
Investor Brand Network
Topics
Initial Public Offering
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Invited to Submit Full Proposal for DoD-Funded Ovarian Cancer Diagnostic Study
July 24, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host July 22 Livestream on Autoimmune Therapeutics Subsidiary Adimune
July 22, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) CEO to Present at Wall Street Reporter’s NEXT SUPER STOCK Event June 26
June 26, 2025
Via
Investor Brand Network
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
June 09, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
June 09, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Terminates Acquisition Agreement with Appili Therapeutics
May 19, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights ADI-100 Developments in Weekly Update Featuring Leadership Team
May 02, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Mayo Clinic’s Dr. Charles Howe in May 2 Update on ADI-100™ Preclinical Study
April 17, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Gains IRB Approval for Endometriosis Diagnostic Study
April 16, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Nasdaq Compliance, Hearing Canceled
April 09, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Appili CEO in April 4 Update Focused on Infectious Disease Innovation
April 02, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights CaSe Platform Acquisition in Weekly Update Focused on Early Cancer Detection
March 28, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Acquires Patents for DNA Damage Detection in Cancer Prevention
March 24, 2025
Via
Investor Brand Network
Topics
Intellectual Property
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Provides Update on Appili Therapeutics Acquisition and Federal Funding Applications
March 18, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Provides Corporate Update, Announces Weekly Investor Series
March 17, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Advances ADI-100 Autoimmune Therapy Toward Clinical Trials
March 06, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Engages Lead Underwriter for Planned IPO
February 21, 2025
Via
Investor Brand Network
Topics
Initial Public Offering
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) to Host Fireside Chat on Feb. 21 to Discuss Key Corporate Developments
February 13, 2025
Via
Investor Brand Network
Topics
Initial Public Offering
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Explores IPO for Pearsanta to Advance Early Cancer Detection
January 13, 2025
Via
Investor Brand Network
Topics
Initial Public Offering
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Subsidiary Advances ADI-100 Gene Therapy Toward Human Trials
December 12, 2024
Via
Investor Brand Network
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
December 12, 2024
From
Aditxt, Inc.
Via
Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Updates Shareholders on Equity Issuance and Shift to Debt Financing Strategy
November 08, 2024
Via
Investor Brand Network
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
November 08, 2024
From
Aditxt, Inc.
Via
Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Acquisition of Appili Therapeutics Moves Forward with Overwhelming Shareholder Approval
November 07, 2024
Via
Investor Brand Network
Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
November 07, 2024
From
Aditxt, Inc.
Via
Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Gains Support for Evofem Merger as Voting Agreements Secure Favorable Votes
November 06, 2024
Via
Investor Brand Network
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
November 06, 2024
From
Aditxt, Inc.
Via
Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Hold CEO-Led Update and Q&A Session Covering Company Developments
October 31, 2024
Via
Investor Brand Network
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
October 31, 2024
From
Aditxt, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
